NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Lastly, to confirm that the KDM6A-TRKA mechanism revealed in the cell line experiments was relevant to CML in vivo, we undertook knockdown of KDM6A in fresh bone marrow isolates from three newly diagnosed CML patients (Table S1).